Pancreatic Cancer Clinical Trials in Nashville, Tennessee

18 studies are recruiting for pancreatic cancer in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

   This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   20 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT07277413 on ClinicalTrials.gov

2. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   48 in total

   Run by

   Immuneering Corporation

   See if you can join NCT07562152 on ClinicalTrials.gov

3. Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

   The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   74 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07252232 on ClinicalTrials.gov

4. Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   49 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07491445 on ClinicalTrials.gov

5. A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

   AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be re…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Center, Nashville, Tennessee

   Locations

   7 in total

   Run by

   Angiex, Inc.

   See if you can join NCT06440005 on ClinicalTrials.gov

6. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

7. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

   The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute - Pharmacy, Nashville, Tennessee

   Locations

   31 in total

   Run by

   Pfizer

   See if you can join NCT07090499 on ClinicalTrials.gov

8. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

   Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   16 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT04981119 on ClinicalTrials.gov

9. DESTINY-PANTUMOUR04

   This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

   Stage

   Not phased

   Ages

   18 to 130

   Site

   Research Site, Nashville, Tennessee

   Locations

   18 in total

   Run by

   AstraZeneca

   See if you can join NCT07124000 on ClinicalTrials.gov

10. A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

    This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute, Nashville, Tennessee

    Locations

    21 in total

    Run by

    ArriVent BioPharma, Inc.

    See if you can join NCT07066657 on ClinicalTrials.gov

11. A Study of PHN-012 in Patients With Advanced Solid Tumors

    This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    PHN-012-001 Site, Nashville, Tennessee

    Locations

    26 in total

    Run by

    Pheon Therapeutics

    See if you can join NCT07127874 on ClinicalTrials.gov

12. A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

    The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    SCRI Oncology Partners, Nashville, Tennessee

    Locations

    28 in total

    Run by

    Jazz Pharmaceuticals

    See if you can join NCT06695845 on ClinicalTrials.gov

13. A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

    RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon, SCRI Oncology Partners, Nashville, Tennessee

    Locations

    3 in total

    Run by

    RasCal Therapeutics, Inc.

    See if you can join NCT04678648 on ClinicalTrials.gov

14. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute, Nashville, Tennessee

    Locations

    6 in total

    Run by

    ModeX Therapeutics, An OPKO Health Company

    See if you can join NCT06239194 on ClinicalTrials.gov

15. Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients

    RATIONALE: Studying samples of tissue, blood, urine, stool, and other biological fluids from patients with cancer and from healthy volunteers undergoing colonoscopy or endoscopy may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This research study is looking at g…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Veterans Affairs Medical Center - Nashville, Nashville, Tennessee

    Locations

    2 in total

    Run by

    Vanderbilt University Medical Center

    See if you can join NCT00899626 on ClinicalTrials.gov

16. Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response

    The goal of this study is to investigate whether the therapeutic response of pancreatic tumors can be accurately assessed using quantitative DCE-MRI, when the inter/intra-scanner variability is reduced using the Point-of-care Portable Perfusion Phantom, P4. The intra-scanner variability over time l…

    Stage

    Not phased

    Ages

    19 and older

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Locations

    2 in total

    Run by

    Ohio State University

    See if you can join NCT04588025 on ClinicalTrials.gov

17. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

    This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gast…

    Stage

    Not phased

    Ages

    40 and older

    Site

    Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

    Locations

    17 in total

    Run by

    Adela, Inc

    See if you can join NCT05366881 on ClinicalTrials.gov

18. A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

    ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to char…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    SCRI Oncology Partners, Nashville, Tennessee

    Locations

    4 in total

    Run by

    AtlasMedx, Incorporated

    See if you can join NCT04503265 on ClinicalTrials.gov